Lisaftoclax (APG-2575) Demonstrates Activity and Safety When Given with Accelerated Ramp-up and then Combined with Acalabrutinib or Rituximab in Patients (pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Including Those with Prior Exposure to VenetoclaxMatthew S. Davids, Yifan Zhai, Larysa Nogaieva et al.|Blood|2024Cited by 8
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMatthew S. Davids, Yifan Zhai, Asher Chanan‐Khan et al.|Med|2025Cited by 6